TRCT
PACB icon

Tower Research Capital (TRC)’s Pacific Biosciences PACB Stock Holding History

Tower Research Capital (TRC)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.7K Buy
50,517
+42,585
+537% +$76.2K ﹤0.01% 2504
2025
Q4 		$14.8K Sell
7,932
-82,983
-91% -$159K ﹤0.01% 3331
2025
Q3 		$116K Sell
90,915
-13,039
-13% -$17.7K ﹤0.01% 1879
2025
Q2 		$129K Buy
103,954
+7,497
+8% +$8.66K ﹤0.01% 2167
2025
Q1 		$114K Buy
96,457
+87,658
+996% +$134K ﹤0.01% 1705
2024
Q4 		$16.1K Sell
8,799
-3,190
-27% -$6.23K ﹤0.01% 3369
2024
Q3 		$20.4K Sell
11,989
-32,674
-73% -$53.7K ﹤0.01% 3227
2024
Q2 		$61.2K Buy
44,663
+40,713
+1,031% +$82.2K ﹤0.01% 2940
2024
Q1 		$14.8K Sell
3,950
-62,246
-94% -$364K ﹤0.01% 3284
2023
Q4 		$649K Buy
66,196
+57,918
+700% +$474K 0.01% 1171
2023
Q3 		$69.1K Sell
8,278
-3,190
-28% -$36.5K ﹤0.01% 2272
2023
Q2 		$153K Sell
11,468
-25,911
-69% -$315K 0.01% 1742
2023
Q1 		$433K Buy
37,379
+35,503
+1,892% +$353K 0.01% 920
2022
Q4 		$16K Sell
1,876
-74,575
-98% -$643K ﹤0.01% 3366
2022
Q3 		$444K Buy
76,451
+64,294
+529% +$369K 0.01% 1247
2022
Q2 		$54K Sell
12,157
-2,779
-19% -$16.9K ﹤0.01% 2807
2022
Q1 		$136K Buy
14,936
+5,639
+61% +$64.9K ﹤0.01% 2003
2021
Q4 		$190K Sell
9,297
-5,866
-39% -$142K ﹤0.01% 1812
2021
Q3 		$387K Buy
15,163
+4,353
+40% +$129K 0.01% 1174
2021
Q2 		$378K Sell
10,810
-53,359
-83% -$1.55M 0.01% 1410
2021
Q1 		$2.14M Buy
64,169
+44,508
+226% +$1.56M 0.04% 462
2020
Q4 		$510K Sell
19,661
-130,267
-87% -$2.21M 0.02% 977
2020
Q3 		$1.48M Buy
149,928
+119,205
+388% +$686K 0.02% 620
2020
Q2 		$106K Buy
30,723
+22,334
+266% +$76K ﹤0.01% 2400
2020
Q1 		$26K Buy
8,389
+1,332
+19% +$5.45K ﹤0.01% 1596
2019
Q4 		$36K Buy
7,057
+6,370
+927% +$32.4K ﹤0.01% 1545
2019
Q3 		$4K Buy
+687
New +$3.84K ﹤0.01% 3438
2019
Q2 		– Sell
-2,187
Closed -$16K – 4117
2019
Q1 		$16K Buy
+2,187
New +$15.8K ﹤0.01% 2402
2018
Q4 		– Sell
-19,897
Closed -$107K – 4211
2018
Q3 		$107K Buy
+19,897
New +$85.4K 0.01% 1302
2018
Q2 		– Sell
-20,841
Closed -$43K – 3949
2018
Q1 		$43K Buy
+20,841
New +$54.1K ﹤0.01% 1756
2017
Q4 		– Sell
-11,673
Closed -$61K – 3872
2017
Q3 		$61K Buy
+11,673
New +$50.2K 0.01% 1790
2017
Q2 		– Sell
-201
Closed -$1K – 3238
2017
Q1 		$1K Sell
201
-8,324
-98% -$40.7K ﹤0.01% 2821
2016
Q4 		$32K Buy
8,525
+8,244
+2,934% +$59.9K ﹤0.01% 1741
2016
Q3 		$3K Sell
281
-8,883
-97% -$74.3K ﹤0.01% 2874
2016
Q2 		$64K Buy
9,164
+8,792
+2,363% +$80.3K 0.01% 1396
2016
Q1 		$3K Buy
+372
New +$3.66K ﹤0.01% 3137
2015
Q4 		– Sell
-11,824
Closed -$43K – 4899
2015
Q3 		$43K Buy
+11,824
New +$57.8K ﹤0.01% 1129
2015
Q1 		– Sell
-200
Closed -$2K – 4783
2014
Q4 		$2K Sell
200
-948
-83% -$6.07K ﹤0.01% 3364
2014
Q3 		$6K Buy
1,148
+453
+65% +$2.37K ﹤0.01% 3173
2014
Q2 		$4K Buy
695
+595
+595% +$2.98K ﹤0.01% 3013
2014
Q1 		$1K Sell
100
-100
-50% -$632 ﹤0.01% 4186
2013
Q4 		$1K Sell
200
-11,087
-98% -$50.9K ﹤0.01% 4237
2013
Q3 		$62K Buy
11,287
+9,287
+464% +$32.2K 0.01% 1722
2013
Q2 		$5K Buy
+2,000
New +$4.98K ﹤0.01% 2950

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tower Research Capital (TRC)'s PACB Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Pacific Biosciences (PACB) stake by 537% in Q1 2026, buying an estimated $76.2K and bringing the position to 50,517 shares worth $66.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2504.

Tower Research Capital (TRC) first reported a position in PACB in Q2 2013 and has held it in 44 quarters since. The position peaked at $2.14M in Q1 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Tower Research Capital (TRC) held 50,517 shares of Pacific Biosciences worth $66.7K as of Q1 2026.
  • Tower Research Capital (TRC) bought 42,585 Pacific Biosciences shares in Q1 2026, an estimated $76.2K.
  • Pacific Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2504 holding.
  • Tower Research Capital (TRC) first reported a position in Pacific Biosciences in Q2 2013 and has held it in 44 quarters since.
  • Tower Research Capital (TRC)'s Pacific Biosciences position peaked at $2.14M in Q1 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.